Dr. Andy Smith discusses valuations of profitable biotech and
pharma companies relative to history, concluding that indications
show biotech is too cheap at the current time. The discussion
explores the PE values of various companies and how these have
changed over time.
First in a series of expert analysis and commentary on the Healthcare sector. Join the discussion and leave your comments and feedback for more on this and other upcoming Global Healthcare sector topics.